CN104411288B - 1‑羟基3,5‑双(4’羟基苯乙烯基)苯的局部施用 - Google Patents
1‑羟基3,5‑双(4’羟基苯乙烯基)苯的局部施用 Download PDFInfo
- Publication number
- CN104411288B CN104411288B CN201380035518.2A CN201380035518A CN104411288B CN 104411288 B CN104411288 B CN 104411288B CN 201380035518 A CN201380035518 A CN 201380035518A CN 104411288 B CN104411288 B CN 104411288B
- Authority
- CN
- China
- Prior art keywords
- skin
- composition
- benzene
- application
- hydroxyls
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title claims abstract description 156
- XLLXMBCBJGATSP-UHFFFAOYSA-N 2-phenylethenol Chemical class OC=CC1=CC=CC=C1 XLLXMBCBJGATSP-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 125000002887 hydroxy group Chemical group [H]O* 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 119
- 238000000034 method Methods 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 238000012545 processing Methods 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 25
- -1 iodopropynyl butyl Chemical group 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000003974 emollient agent Substances 0.000 claims description 16
- 230000000699 topical effect Effects 0.000 claims description 16
- 239000000080 wetting agent Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 230000037303 wrinkles Effects 0.000 claims description 13
- 206010040829 Skin discolouration Diseases 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 230000009759 skin aging Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000007854 depigmenting agent Substances 0.000 claims description 5
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- GHBFNMLVSPCDGN-UHFFFAOYSA-N caprylic acid monoglyceride Natural products CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 3
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- 238000004945 emulsification Methods 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 2
- NMJJFJNHVMGPGM-UHFFFAOYSA-N n-butylmethanoate Natural products CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 claims description 2
- 229950009195 phenylpropanol Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 99
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 66
- 239000002585 base Substances 0.000 description 51
- 238000012360 testing method Methods 0.000 description 42
- 239000000523 sample Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 18
- 230000001629 suppression Effects 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 240000002834 Paulownia tomentosa Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 206010040954 Skin wrinkling Diseases 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 102000003425 Tyrosinase Human genes 0.000 description 10
- 108060008724 Tyrosinase Proteins 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000186427 Cutibacterium acnes Species 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 208000003351 Melanosis Diseases 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 230000016571 aggressive behavior Effects 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000004885 piperazines Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229940055019 propionibacterium acne Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000004492 retinoid derivatives Chemical class 0.000 description 5
- 229960003471 retinol Drugs 0.000 description 5
- 235000020944 retinol Nutrition 0.000 description 5
- 239000011607 retinol Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 208000000069 hyperpigmentation Diseases 0.000 description 4
- 230000003810 hyperpigmentation Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- FCSLKRVBOXMLOR-UHFFFAOYSA-N N1CCNCC1.C1=CC=CC=C1 Chemical compound N1CCNCC1.C1=CC=CC=C1 FCSLKRVBOXMLOR-UHFFFAOYSA-N 0.000 description 3
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 150000003712 vitamin E derivatives Chemical class 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 2
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000005903 Dioscorea Nutrition 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010027146 Melanoderma Diseases 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 150000005204 hydroxybenzenes Chemical class 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 206010024217 lentigo Diseases 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 201000003385 seborrheic keratosis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229920005573 silicon-containing polymer Polymers 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical compound CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical class OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical class OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical class COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N 2-butanol Substances CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- CARAGGJGMNFWBG-UHFFFAOYSA-N 3-(2-phenylethyl)benzene-1,2-diol Chemical compound OC1=CC=CC(CCC=2C=CC=CC=2)=C1O CARAGGJGMNFWBG-UHFFFAOYSA-N 0.000 description 1
- ORWQBKPSGDRPPA-UHFFFAOYSA-N 3-[2-[ethyl(methyl)amino]ethyl]-1h-indol-4-ol Chemical compound C1=CC(O)=C2C(CCN(C)CC)=CNC2=C1 ORWQBKPSGDRPPA-UHFFFAOYSA-N 0.000 description 1
- LHJCLTLPXXKFTJ-UHFFFAOYSA-N 3-[4-hydroxy-3-(4-hydroxy-3-prop-2-enylphenyl)phenyl]propane-1,2-diol Chemical compound OCC(O)CC1=CC=C(O)C(C=2C=C(CC=C)C(O)=CC=2)=C1 LHJCLTLPXXKFTJ-UHFFFAOYSA-N 0.000 description 1
- HOCCFHXBGWEJEQ-UHFFFAOYSA-N 4-[3-(2,4-dimethoxy-3-methylphenyl)propyl]benzene-1,3-diol Chemical compound COC1=C(C)C(OC)=CC=C1CCCC1=CC=C(O)C=C1O HOCCFHXBGWEJEQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical class COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000065610 Cotinus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001424688 Enceliopsis Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- DRDRYGIIYOPBBZ-XBXARRHUSA-N Licochalcone B Natural products COC1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1 DRDRYGIIYOPBBZ-XBXARRHUSA-N 0.000 description 1
- WBDNTJSRHDSPSR-UHFFFAOYSA-N Licochalcone C Natural products C1=CC(O)=C(CC=C(C)C)C(OC)=C1C=CC(=O)C1=CC=C(O)C=C1 WBDNTJSRHDSPSR-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 229930182636 Magnolignan Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 229940124200 Melanin inhibitor Drugs 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001629585 Paulownia fortunei Species 0.000 description 1
- 241001223148 Paulownia kawakamii Species 0.000 description 1
- 241000450245 Paulownia taiwaniana Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010050637 Skin tightness Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- JSXROLUNEDJZJE-UHFFFAOYSA-N acetic acid;phenol Chemical class CC(O)=O.OC1=CC=CC=C1 JSXROLUNEDJZJE-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000012874 anionic emulsifier Substances 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical class COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940111782 egg extract Drugs 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- ZWMHKXYQHNWDRX-UHFFFAOYSA-N ethanol;propane-1,1-diol Chemical class CCO.CCC(O)O ZWMHKXYQHNWDRX-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- FNNJSYRQSGKSAY-UHFFFAOYSA-N hexadecyl 4-(aminomethyl)cyclohexane-1-carboxylate Chemical group CCCCCCCCCCCCCCCCOC(=O)C1CCC(CN)CC1 FNNJSYRQSGKSAY-UHFFFAOYSA-N 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229930187586 licochalcone Natural products 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 108010062085 ligninase Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229910001562 pearlite Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 150000003782 β-tocotrienols Chemical class 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 150000003786 γ-tocotrienols Chemical class 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 150000003790 δ-tocotrienols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及包含1‑羟基3,5‑双(4’羟基苯乙烯基)苯或其美容上可接受的盐的组合物,以及使用所述组合物处理人皮肤的方法。
Description
技术领域
本发明涉及用于1-羟基3,5-双(4’羟基苯乙烯基)苯的局部施用的组合物和方法。
背景技术
已知为皮肤提供活性剂以用于处理皮肤老化迹象、为皮肤提供抗炎有益效果或增亮皮肤的目的。
特定种类的抗炎剂是抑制细胞转录因子核因子κ-B(NFKB)的抗炎剂。例如,已知某些取代的间苯二酚(例如4-己基间苯二酚和四氢姜黄素)是NFKB抑制剂。当施用于皮肤时,此类化合物提供抗衰老有益效果。然而,仅相对少量的化合物已鉴定为有效和美容上可接受的。
已知向皮肤施用抗炎化合物以提供抗色素沉着有益效果。用于该目的的特定种类的抗炎剂是借助于抑制炎症调节剂分子来减少黑素细胞中黑色素量的试剂。然而,仅相对少量的化合物已鉴定为适合于局部使用,以调节皮肤中的黑色素形成。
发明内容
本发明人现在已惊奇地发现1-羟基3,5-双(4’羟基苯乙烯基)苯是有效的NFKB抑制剂,并且适合于局部地施用于皮肤,并且1-羟基3,5-双(4’羟基苯乙烯基)苯及其美容上可接受的盐可用于处理皮肤老化迹象,是黑素细胞中的黑色素形成的抑制剂,并且可施用于需要亮肤处理的皮肤。
在一个方面,本发明提供了包含下述的组合物:1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐;以及美容上可接受的局部用载体,所述美容上可接受的局部用载体包含选自润湿剂、乳化剂、润肤剂、湿润剂和芳香剂的成分。
本发明还提供了处理人皮肤的方法,所述方法包括向所述人皮肤局部地施用包含1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐的组合物。
本发明还提供了处理皮肤老化迹象的方法,所述方法包括向需要此类处理的皮肤局部地施用包含1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐的组合物。
本发明提供了亮肤的方法,所述方法包括向需要亮肤处理的皮肤局部地施用包含1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐的组合物的步骤。
本发明还提供了抑制微生物生长的方法,所述方法包括向所述微生物施用1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐。
通过本发明的具体实施方式和权利要求书,本发明的其他特征和优点将显而易见。
具体实施方式
据信根据本文的描述,本领域的技术人员可最大限度地利用本发明。下面的具体实施例应该理解为仅仅是示例性的,并且无论如何都不会以任何方式限制本公开的其余部分。
除非另有规定,否则本文使用的所有技术和科学术语都具有本发明所属技术领域普通技术人员公知的相同含义。另外,将本文提及的所有出版物、专利申请、专利及其他参考文献以引用方式并入本文中。除非另外指明,否则百分比或浓度指重量百分比或重量浓度(即%(W/W))。除非另有说明,否则所有范围包括端值,例如“4至9”包括端值4和9。
本文所描述的产物可任选为成品包装形式。在一个实施例中,所述包装为装有所述组合物的诸如塑料、金属或玻璃管或广口瓶之类的容器。该产品可另外具有用于储存该容器的诸如塑料或纸板盒之类的包装。在一个实施例中,该产品包含本发明的组合物并且具有引导使用者将该组合物施用至皮肤以处理如下文论述的皮肤老化迹象的说明书。这种说明书可印刷在容器上、标签插页或任何其它包装上。
如本文所用,“局部地施用”意指例如利用手或诸如擦拭物、辊或喷雾器之类的施用器,直接涂抹或散布在外部皮肤、头皮或毛发上。
如本文所用,“美容上可接受的”意指该术语所描述的成分适用于与组织(例如皮肤或毛发)接触而无不当的毒性、不相容性、不稳定性、刺激性、变应性反应或类似症状。
如本文所用,“美容品”指能保持、恢复、赋予、刺激或增强体美外观或看起来能增进美貌或年轻的美容物质或制品,尤其是涉及组织或皮肤的外观时。
如本文所用,“需要处理老化迹象的皮肤”意指但不限于松垂、松弛、松散、粗糙、有皱纹、变薄或不平的皮肤。改善老化迹象意指改善皮肤紧致度、改善皮肤肌理、改善皮肤上的皱纹出现、改善皮肤色调或处理皮肤中的外部侵害。
如本文所用,“改善皮肤的紧致度”意指增强皮肤的紧致度或弹性、预防皮肤的紧致度或弹性损失、或者预防或处理松垂、松懈和松弛的皮肤。皮肤的紧致度或弹性可通过使用皮肤弹性测试仪(cutometer)测量。参见Handbook of Non-Invasive Methods and theSkin,J.Serup,G.Jemec和G.Grove编辑,第66.1章(2006)。皮肤弹性或紧致度的损失可能是多种因素造成的,所述因素包括但不限于老化、环境损害或向皮肤施用化妆品的结果。
如本文所用,“改善皮肤的肌理”意指使皮肤表面平滑以除去皮肤表面上的隆起块或裂隙。
如本文所用,“改善皮肤上的皱纹出现”意指预防、延迟、停滞或逆转皮肤上的皱纹形成的过程。如本文所用,“皱纹”包括细纹、细皱纹或粗皱纹。皱纹的例子包括但不限于眼睛周围的微细纹(例如“鱼尾纹”)、前额和颊皱纹、眉心纹和嘴巴周围的笑纹。
如本文所用,“肤色不均”意指与弥漫状或斑驳状色素沉着有关的皮肤状况,所述色素沉着可分类为色素沉着过度,例如发炎后色素沉着过度。
如本文所用,“斑点”意指与发红或红斑相关的皮肤状况。
如本文所用,“处理皮肤中的外部侵害”意指减少或预防皮肤中外部侵害带来的损害。外部侵害的例子包括但不限于使用清洁剂(如,含有表面活性剂的局部用清洁剂)、化妆品、剃须以及环境损害(如,来自UV光照(如,来自日光的阳光损害或来自非天然来源(如UV灯和太阳模拟器)的损害)、臭氧、废气、污染、氯和含氯化合物以及抽烟烟雾)对皮肤的损害。外部侵害对皮肤的影响包括但不限于对脂质、碳水化合物、肽、蛋白质、核酸和维生素的氧化和/或亚硝化损伤和对这些物质的修饰。外部侵害对皮肤的影响还包括但不限于细胞活力的损失、细胞功能的损失或改变以及基因和/或蛋白质表达的变化。
如本文所用,“改善肤色”是指增亮皮肤外观(如,增亮色素斑痕或病损、减轻皮肤灰黄、和/或均匀皮肤的颜色)。
如本文所用,“需要减轻皮肤炎症的皮肤”是指表现出发红或红斑、浮肿或对外部因素具有反应性或过敏性的皮肤。外部因素包括但不限于太阳光线(UV、可见光、IR)、微生物、大气污染物(例如臭氧)、废气污染物、氯和产生氯的化合物、抽烟烟雾、低温、热。可通过使用本发明的组合物来治疗或预防的炎性疾病和相关病症包括但不限于如下:关节炎、支气管炎、接触性皮炎、特应性皮炎、牛皮癣、皮脂溢性皮炎、湿疹、过敏性皮炎、多形性日光疹、炎性皮肤病、毛囊炎、脱发、毒藤疹、虫咬发炎、粉刺发炎、因外源性因素(包括但不限于化学品、创伤、污染物(例如抽烟烟雾)和日光照射)引起的刺激、因发炎导致的次级病症(包括但不限于干燥病、角化过度、瘙痒、发炎后色素沉着过度、结瘢等)。优选的是,可使用本发明的方法治疗或预防的炎性疾病和相关病症为关节炎、炎性皮肤病、接触性皮炎、过敏性皮炎、特应性皮炎、多形性日光疹、刺激(包括因外源性因素引起的红斑)、粉刺发炎、牛皮癣、皮脂溢性皮炎、湿疹、毒藤疹、虫咬发炎、毛囊炎、脱发以及次级病症等等。
如本文所用,术语“增亮皮肤”通常指使肤色、皮肤颜色和/或皮肤色度变淡、变亮、变白和/或均匀,和/或指祛黄,和/或指色素斑痕和/或病损(包括但不限于色素斑、黑色素斑、老年斑、日晒斑、衰老性着色斑、雀斑(freckles)、单纯性雀斑痣、色素性日光性角化病、脂溢性角化病、黑斑病、痤疮斑痕、发炎后色素沉着过度、着色斑、雀斑(ephelides)、它们中两种或更多种的组合等等)的淡化和/或褪色。在某些实施例中,“增亮皮肤”还指增加的皮肤光亮度、光泽度、半透明度和/或发光和/或获得更光亮、光泽、半透明的或发光的肤色外观或较低的黄色或萎黄色肤色。在某些优选的实施例中,“增亮皮肤”指使肤色增亮和均匀,增加皮肤光亮度和/或淡化老年斑。
如本文所用,术语“需要亮肤处理的皮肤”通常是指显示一种或多种选自以下特性的皮肤:如根据2007年公布的COLIPA指南:用于皮肤颜色分型的比色测定和无紫外线暴露的最小红斑量(MED)预测的指南(COLIPA GUIDELINE:GUIDELINE FOR THE COLORIMETRICDETERMINATION OF SKIN COLOUR TYPING AND PREDICTION OF THE MINIMAL ERYTHEMALDOSE(MED)WITHOUT UV EXPOSURE)(其以引用的方式并入本文并且在下文进一步描述)所确定的,具有低于41的测量的个体类型角(ITA)值的皮肤,发暗和/或萎黄的皮肤,包括UV暗化的皮肤,具有不均匀皮肤色调的皮肤,或具有一处或多处色素沉着的斑痕和/或病损(包括但不限于色素斑、黑色素斑、老年斑、日晒斑、老年性雀斑痣、雀斑、单纯性雀斑痣、色素性日光性角化病、脂溢性角化病、黑斑病、痤疮斑痕、炎症后色素沉着过度、着色斑、雀斑、其中两种或更多种的组合等等)的皮肤。在COLIPA指南中,肤色被定义为ITA值的函数:非常亮白的皮肤>55;亮白皮肤41-55,中间态皮肤28-41和棕褐色皮肤<28。在某些优选的实施例中,“需要亮肤的皮肤”指皮肤的ITA值低于41,例如约40或更低,约35或更低,约30或更低,或更优选约28或更低的个体。在某些其他优选的实施例中,本发明涉及用于选自萎黄和/或暗化皮肤的需要亮肤处理的皮肤上的组合物和方法。在某些其他优选的实施例中,本发明涉及用于需要进行选自老年斑、雀斑、痤疮后留下的斑痕以及它们中两种或更多种的组合的亮肤处理的组合物和方法。
如本文所用,除非另外指明,否则组合物中所有的成分百分比均为活性/固体成分的重量百分比(按组合物的总重量计)。
如本文所用,“基本上不含”成分意指含有按重量计小于约1%,例如按重量计小于约0.5%,例如按重量计小于约0.25%,例如按重量计小于约0.1%的此类成分。在一个实施例中,“基本上不含”意指完全不含此类成分。
本发明的组合物适合于就皮肤老化迹象或炎症处理人皮肤,例如在面部或身体上的皮肤。在特别优选的实施例中,根据本发明的组合物用于处理细纹和皱纹的存在和/或弹性丧失。本发明的组合物适合于处理人皮肤,例如在面部或身体上的皮肤,以增亮皮肤。
1-羟基3,5-双(4’羟基苯乙烯基)苯
本发明的组合物包含1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐。
1-羟基3,5-双(4’羟基苯乙烯基)苯是具有下文结构的姜黄素类似物:
如美国专利7,745,670中所述,1-羟基3,5-双(4’羟基苯乙烯基)苯可通过下述进行制备:使用阿尔布佐夫反应(Arbuzov reaction),使1-(溴甲基)-4-甲氧基苯与磷酸三乙酯反应,以产生[(4-甲氧基苯基)甲基]膦酸二乙酯。使用THF中的氢化钠作为碱,使[(4-甲氧基苯基)甲基]膦酸二乙酯与5-甲氧基苯-1,3-二甲醛偶联,随后与三氯化硼和二氯甲烷反应,以用羟基取代甲氧基基团。
1-羟基3,5-双(4’羟基苯乙烯基)苯的盐可通过例如下述进行制备:使1-羟基3,5-双(4’羟基苯乙烯基)苯与碱例如哌嗪或另一种碱反应,以产生1-羟基3,5-双(4’羟基苯乙烯基)苯的至少一些酚盐。
局部用组合物
一般来讲,1-羟基3,5-双(4’羟基苯乙烯基)苯或其盐以美容上有效的量存在于组合物中,所述量例如按组合物的重量计约0.01%至约10%、优选约0.1%至约5%、更优选约0.2%至约2%、甚至更优选约0.5%至约1.5%。
本发明的组合物可局部地施用至人皮肤和/或毛发。
组合物可为可涂抹的。它们可通过涂抹局部地施用,例如涂抹在皮肤或毛发上,特别是涂抹在面部或手部的皮肤上。
在一个实施例中,本发明的组合物无需电压而局部地施用。
除1-羟基3,5-双(4’羟基苯乙烯基)苯之外,该组合物还可包括美容上可接受的局部用载体,所述美容上可接受的局部用载体可为按组合物重量计的约50%至约99.99%(例如按组合物重量计的约80%至约99%)。在本发明的优选实施例中,美容上可接受的局部用载体包括水。
美容上可接受的局部用载体可能不适合于摄入。
美容上可接受的局部用载体可包括选自下述五种中的一种或多种的成分:润湿剂、乳化剂、润肤剂、湿润剂和芳香剂。在某些实施例中,美容上可接受的局部用载体包括来自上述种类中的两种或更多种的成分,例如来自这些种类中的至少三种或更多种的成分。
在一个实施例中,美容上可接受的局部用载体包括水、乳化剂和润肤剂。
可将组合物制备成多种产品类型,包括但不限于洗剂、霜剂、凝胶剂、棒剂、喷雾剂、油膏剂、清洁液体洗剂和固体皂剂、洗发剂和毛发调理剂、毛发固定剂、糊剂、泡沫剂、粉末剂、摩丝、剃须膏、擦拭物、贴剂、水凝胶、成膜产品、面膜和皮肤膜剂、膜剂和化妆品如粉底以及睫毛膏。这些产品类型可含有几种类型的美容上可接受的局部用载体,包括但不限于溶液、悬浮液、乳液(例如微乳液和纳米乳液)、凝胶、固体和脂质体。
可用于本发明的组合物可配制成溶液剂。溶液通常包括水性或有机溶剂(例如约50%至约99.99%或约90%至约99%的美容上可接受的水性或有机溶剂)。合适的有机溶剂的例子包括湿润剂(例如保水材料或吸湿材料),例如丙二醇、戊二醇、聚乙二醇、聚丙二醇、甘油、1,2,4-丁三醇、山梨醇酯、1,2,6-己三醇;以及乙醇及其混合物。溶液可任选包括润湿剂例如以提供泡沫,所述润湿剂例如阴离子型、非离子型或阳离子型润湿剂。
可用于本主题发明的组合物可配制成包含润肤剂的溶液。此类组合物优选包含约2%至约50%的一种或多种润肤剂。如本发明所用,“润肤剂”指用于预防或减轻干燥,例如通过防止皮肤水分经皮肤损失的物质。润肤剂的例子包括疏水化合物例如植物油、矿物油(例如凡士林)、脂肪酯(例如棕榈酸异丙酯、c12-c15烷基苯甲酸酯)包括甘油、硅油(例如聚二甲基硅氧烷)等等的那些脂肪酯。
洗剂可以由此类溶液制成。洗剂通常含有约1%至约20%(例如,约5%至约10%)的一种或多种润肤剂和约50%至约90%(例如,约60%至约80%)的水分。
可由溶液配制的另一种产品是霜剂。霜剂通常包含约5%至约50%(例如,约10%至约20%)的一种或多种润肤剂和约45%至约85%(例如,约50%至约75%)的水分。
尽管优选的是本发明的组合物包含水,但作为另一种选择该组合物可以是无水的或为不包含水而是包含有机和/或有机硅溶剂、油脂、类脂和蜡的油膏剂。油膏剂可含有动物或植物油或半固体烃的简单基料。油膏剂可包含约2%至约10%的一种或多种润肤剂加上约0.1%至约2%的一种或多种增稠(胶凝)剂。
可将该组合物配制为乳剂。如果局部用载体是乳液,则约1%至约10%(如约2%至约5%)的该局部用载体含有一种或多种乳化剂。乳化剂可以为非离子型、阴离子型或阳离子型。合适乳化剂的例子包括在个人护理和化妆品制剂领域中通常鉴定为此类的乳化剂,例如阳离子型乳化剂例如二硬脂基二甲基氯化铵、非离子型乳化剂例如硬脂基聚氧乙烯醚-2、硬脂基聚氧乙烯醚-21;阴离子型乳化剂例如十六烷基磷酸钾;聚合物型乳化剂例如丙烯酰基二甲基牛磺酸酯/VP共聚物等等。
洗剂和软膏可配制成乳状液。通常这类洗剂含有0.5%至约5%的一种或多种乳化剂。这种霜剂可含有约1%至约20%(如约5%至约10%)的一种或多种润肤剂;约20%至约80%(如30%至约70%)的水;和约1%至约10%(如约2%至约5%)的一种或多种乳化剂。
水包油和油包水型单乳液护肤制剂,例如洗剂和霜剂是化妆品领域所熟知的,并且可用于本主题发明。多相乳状液组合物(例如水包油包水型或油包水包油型)也可用于本主题发明。通常,此类单相乳状液或多相乳状液含有水分、润肤剂和乳化剂作为其基本成分。
本发明的组合物还可被配制成凝胶(如,含水的、醇、醇/水或油性凝胶,使用适宜的胶凝剂)。用于水性凝胶和/或醇凝胶的合适胶凝剂包括但不限于天然树胶、(交联)丙烯酸和丙烯酸酯聚合物和共聚物以及纤维素衍生物(例如羟甲基纤维素和羟丙基纤维素)。用于油(例如矿物油)的适当胶凝剂包括但不限于氢化丁烯/乙烯/苯乙烯共聚物和氢化乙烯/丙烯/苯乙烯共聚物。此类凝胶通常包含按重量计约0.1%至5%的此类胶凝剂。
本发明的组合物也可配制成固体制剂(例如蜡基棒剂、条皂组合物、粉剂或含有粉剂的擦拭物)。
除了上述组分外,可用于本主题发明的组合物还可含有多种在常规上以其技术领域确定的水平用于在皮肤和毛发上使用的组合物中的其他油溶性物质和/或水溶性物质。
另外的美容活性剂
在一个实施例中,该组合物包括另外的NFKB-抑制剂,例如取代的间苯二酚、(E)-3-(4-甲基苯磺酰基)-2-丙烯腈(例如“Bay 11-7082”,商购自Sigma-Aldrich ofSt.Louis,Missouri)、四氢姜黄素(例如四氢姜黄素CG,购自Sabinsa Corporation ofPiscataway,NJ)、泡桐素、泡桐属(Paulownia)木材(例如毛泡桐(Paulownia tomentosa)、白花泡桐(Paulownia fortunei)、泡桐(Paulownia elongate)、台湾泡桐(Paulowniataiwaniana)和/或台湾泡桐(Paulownia kawakamii)的木材)的提取物、以及它们的组合。
在一个实施例中,该组合物还含有另外的美容活性剂。如本文所用,“美容活性剂”是对皮肤具有美容或治疗效果的化合物(例如,合成化合物或者从天然来源或天然提取物中分离的化合物),包括但不限于抗老化活性剂、抗炎剂、原弹性蛋白促进剂、抗痤疮剂、抗微生物剂、抗炎剂、抗霉菌剂、外用止痛剂、防晒剂、抗氧化剂、角质层分离剂、维生素、亮肤剂和皮肤紧致剂。
在一个实施例中,该组合物包括亮肤剂例如酪氨酸酶抑制剂、黑色素降解剂、黑素体转移抑制剂包括PAR-2拮抗剂、类视色素、抗氧化剂、氨甲环酸、氨甲环酸十六烷基酯盐酸盐、皮肤漂白剂、亚油酸、腺苷单磷酸二钠盐、洋甘菊(Chamomilla)提取物、尿囊素、遮光剂、滑石或二氧化硅、锌盐等等,或如Solano等人Pigment Cell Res.19(550-571)和Ando等人,Int J Mol Sci 11(2566-2575)中描述的其他试剂。
合适的酪氨酸酶抑制剂的例子包括但不限于维生素C及其衍生物、维生素E及其衍生物、曲酸、熊果苷、间苯二酚、对苯二酚、黄酮(例如甘草类黄酮、甘草根提取物、桑树根提取物、菊叶薯蓣(dioscorea coposita)根提取物、虎耳草提取物等等)、鞣花酸、水杨酸盐和衍生物、葡糖胺和衍生物、富勒烯、桧木醇、二元酸(dioic acid)、乙酰葡糖胺、5,5’-二丙基-联苯-2,2’-二醇(厚朴木酚素)、4-(4-羟基苯基)-2-丁醇(4-HPB)、其中两种或更多种的组合等等。
维生素C衍生物的例子包括但不限于抗坏血酸和盐、抗坏血酸-2-葡糖苷、抗坏血酸磷酸钠、抗坏血酸磷酸镁以及富含维生素C的天然提取物。
维生素E衍生物的例子包括但不限于α-生育酚、β-生育酚、γ-生育酚、δ-生育酚、α-生育三烯酚、β-生育三烯酚、γ-生育三烯酚、δ-生育三烯酚以及它们的混合物、生育酚乙酸酯、生育酚磷酸酯以及富含维生素E衍生物的天然提取物。
间苯二酚衍生物的例子包括但不限于间苯二酚、4-取代的间苯二酚如4-烷基间苯二酚诸如4-丁基间苯二酚(rucinol)、4-己基间苯二酚(SYNOVEA HR,SYNTHEON)、苯乙基间苯二酚(SYMWHITE,SYMRISE)、1-(2,4-二羟基苯基)-3-(2,4-二甲氧基-3-甲基苯基)-丙烷(nivitol,UNIGEN)等等,以及富含间苯二酚的天然提取物。
水杨酸盐的例子包括但不限于4-甲氧基水杨酸钾、水杨酸、乙酰水杨酸、4-甲氧基水杨酸以及它们的盐。
在某些优选的实施例中,酪氨酸酶抑制剂包括4-取代的间苯二酚、维生素C衍生物或维生素E衍生物。在更优选的实施例中,酪氨酸酶抑制剂包括苯乙基间苯二酚、4-己基间苯二酚或抗坏血酸-2-葡糖苷。
合适的黑色素降解剂的例子包括但不限于过氧化物和酶,如过氧化物酶和木素酶。在某些优选的实施例中,黑色素抑制剂包括过氧化物或木素酶。
合适的黑素体转移抑制剂的例子包括PAR-2拮抗剂例如大豆胰蛋白酶抑制剂或Bowman-Birk抑制剂、维生素B3和衍生物例如烟酰胺、大豆精华、全大豆、大豆提取物。在某些优选的实施例中,黑素体转移抑制剂包括大豆提取物或烟酰胺。
类视色素的例子包括但不限于视黄醇(维生素A醇)、视黄醛(维生素A醛)、视黄醇乙酸酯、视黄醇丙酸酯、视黄醇亚油酸酯、视黄酸、视黄醇棕榈酸酯、异维甲酸、他佐罗汀、蓓萨罗丁、阿达帕林、它们的两种或更多种的组合等。在某些优选的实施例中,所述类视色素选自视黄醇、视黄醛、视黄醇乙酸酯、视黄醇丙酸酯、视黄醇亚油酸酯、以及它们的两种或更多种的组合。在某些更优选的实施例中,所述类视色素为视黄醇。
其他亮肤剂包括维生素B5、维生素B12、乙醇酸以及泡桐属木材(例如毛泡桐、白花泡桐、泡桐、台湾泡桐和/或台湾泡桐的木材)的提取物。
抗氧化剂的例子包括但不限于水溶性抗氧化剂如巯基化合物及其衍生物(例如焦亚硫酸钠和N-乙酰基半胱氨酸、谷胱甘肽)、硫辛酸和二氢硫辛酸、茋类化合物如白藜芦醇和衍生物、乳铁蛋白、铁和铜的螯合剂以及抗坏血酸和抗坏血酸衍生物(例如抗坏血酸-2-葡糖苷、抗坏血酸棕榈酸酯和抗坏血酸多肽)。适用于本发明组合物中的油溶性抗氧化剂包括但不限于丁基化羟基甲苯、类视色素(如,视黄醇和视黄醇棕榈酸酯)、生育酚类(例如,生育酚乙酸酯)、生育三烯酚和泛醌。包含适用于本发明的组合物中的抗氧化剂的天然提取物包括但不限于:包含黄酮类和异黄酮类以及它们的衍生物(如,染料木黄酮和二联玉米蛋白)的提取物、包含白藜芦醇的提取物等。此类天然提取物的实例包括葡萄籽、绿茶、红茶、白茶、松树树皮、小白菊、不含小白菊内酯的小白菊、燕麦提取物、黑莓提取物、黄栌提取物、大豆提取物、柚提取物、麦芽精提取物、橙皮素、葡萄提取物、马齿苋提取物、甘草查耳酮、查耳酮、2,2'-二羟查耳酮、报春花提取物、蜂胶,等等。
其他材料
本组合物中还可存在多种其他物质,如本领域已知的。这些物质包括湿润剂、pH调节剂、螯合剂(例如EDTA)、芳香剂、染料和防腐剂(例如BHT、苄醇)。
在一个实施例中,该组合物基本上不含,优选完全不含防腐剂。这是因为优选地,1-羟基3,5-双(4’羟基苯乙烯基)苯及其盐对于抑制和/或杀死微生物是活性的。因此,根据本发明的组合物可配制为含有很少或不含常规防腐剂。常规防腐剂例如选自对羟基苯甲酸酯类、苯甲酸及其盐、苯氧基乙醇、异噻唑酮、咪唑烷基脲、碘代丙炔基氨基甲酸丁酯、DMDM乙内酰脲、辛乙二醇、脱氢乙酸、山梨酸及其盐、氯苯甘醚、辛酸甘油酯、苯丙醇、乙酰丙酸钠、茴香酸、乙基己基甘油、苯甲醇、以及它们的组合。
含有本发明的这种组合物的组合物和制剂以及产品可用本领域普通技术人员熟知的方法制备。
使用方法
本发明的组合物可局部地施用于人皮肤,例如需要处理一处或多处如上所述的皮肤老化迹象的皮肤。在一个实施例中,可将组合物施用至需要处理细纹和皱纹和/或弹性损失的皮肤。可根据合适的处理方案,如每月、每周、每隔一天、每天、每天两次等,将组合物施用至需要这种处理的皮肤。
1-羟基3,5-双(4’羟基苯乙烯基)苯、其美容上可接受的盐和含有其的组合物可用于提供抗微生物效应(例如抗菌、抗真菌、抗病毒或抗寄生虫效应)。
在一个实施例中,本发明提供了抑制微生物生长的方法,所述方法包括向所述微生物施用1-羟基3,5-双(4’羟基苯乙烯基)苯、其美容上可接受的盐或含有其的组合物。
可通过此类施用被抑制或杀死的微生物包括革兰氏阳性菌、革兰氏阴性菌和真菌,包括金黄色葡萄球菌(Staphylococcus aureus)、表皮葡萄球菌(Staphylococcusepidermidis)、痤疮丙酸杆菌(Propionibacterium acnes)、大肠杆菌(Escherichiacoli)、铜绿假单胞菌(Pseudomonas aeruginosa)、白假丝酵母(Candida albicans)、和黑曲霉(Aspergillus niger)。
据信根据本文的描述,本领域的技术人员可最大限度地利用本发明。下面的具体实施例应该理解为仅仅是示例性的,并且无论如何都不会以任何方式限制本公开的其余部分。以下非限制性实例进一步说明了本发明。
实例1:NFKB抑制
用不同浓度的1-羟基3,5-双(4’羟基苯乙烯基)苯和媒介物对照(DMSO)进行NFKB抑制测试。如美国专利7,745,670中所述制备1-羟基3,5-双(4’羟基苯乙烯基)苯。
如下进行NF-KB抑制测试。从ATCC(Manassas,VA.)购买大鼠心肌成肌细胞H9c2细胞。将培养物维持在补充有10%胎牛血清、100单位/ml青霉素和50ug/ml链霉素(Invitrogen life technologies,Carlsbad,CA.)的达尔伯克氏改良伊格尔培养基(DMEM,Invitrogen Life Technologies,Carlsbad,CA.)中。使用Lipofectamine 2000(Invitrogen life technologies,Carlsbad,Calif.),用0.45μg总DNA/孔瞬时转染在96孔板中生长的1×104细胞。在所有转染中,除NF-kB荧光素酶启动子之外,还包括了具有胸苷激酶启动子和海肾荧光素酶报道基因的构建体(pRL-TK,Promega,Madison Wis.)作为内部对照。转染后一天,用指定样品(在作为媒介物的DMSO中)以指定浓度处理细胞,并且用100ng/mL肿瘤坏死因子-α(TNFα,Sigma-Aldrich,St Louis,MO)刺激细胞大约24小时,然后使细胞裂解以用于荧光素酶测定,所述荧光素酶测定使用来自Promega(Madison,Wis.)的双荧光素酶报道基因系统,遵循生产商的方案。简言之,使用来自Molecular Devices(Sunnyvale,Calif.)的光度计LMAX,首先测量萤火虫荧光素酶活性(代表NF-kB启动子活性),然后测量海肾荧光素酶(内部对照)。这两种荧光素酶活性(RLU)的比率用于评估每种启动子的活性:
NF-KB抑制=[1-(RLU样品/RLU对照)]*100
其中RLU样品和RLU和对照分别为所述样品和对照的标准化的荧光素酶活性比率。
结果在表1中示出,在其中记录了NF-kB报道基因激活(发光,L)。还记录了NF-kB抑制百分比。
表1
1-羟基3,5-双(4’羟基苯乙烯基)苯显示在人皮肤细胞中NF-kB介导的炎症应答的大幅减少。
实例2:抗炎活性
如下评估1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐的局部抗炎活性。
表皮等同物(EPI 200HCF),包含正常人表皮角质细胞的多层分化表皮购自MatTek(Ashland,MA)。收到以后,表皮等同物在无氢化可的松的维持培养基中在37℃下温育24小时。在暴露于阳光紫外线(配备有1-mm Schott WG 320滤波器的1000W-Oriel太阳模拟器;施用的紫外线剂量:如在360nm处测量的70kJ/m2)之前,等同物用在70:30乙醇-丙二醇媒介物中的1-羟基3,5-双(4’羟基苯乙烯基)苯局部处理(2mg/cm2)两小时。使等同物在37℃下与维持培养基一起温育24小时,然后使用商购可得的试剂盒(Millipore Corp.,Billerica,MA)分析上清液的IL-8细胞因子释放。
结果在表2中示出。
表2
1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐显示人皮肤细胞中UV诱导的炎症的大幅减少。
实例3:弹性蛋白和胶原1A基因表达的诱导
原代人真皮成纤维细胞(Lifeline Cell Technologies,Frederick,MD)在24孔组织培养板上的DMEM培养基(Invitrogen/Life Technologies,Carlsbad,CA)中生长直至汇合,所述DMEM培养基具有10%FBS和1%青霉素-链霉素,随后用含和不含TNF-a的1-羟基3,5-双(4’羟基苯乙烯基)苯(0.1ug/mL)处理48小时。处理后,使用RLT缓冲液使细胞裂解,并且使用RNeasy迷你试剂盒(RNeasy Mini Kit)(Qiagen,Valencia,CA)分离总RNA。使用基因扩增PCR系统(Gene Amp PCR System)9700和7500实时PCR系统循环仪(AppliedBiosystems/Life Technologies,Carlsbad,CA)进行定量PCR。使用弹性蛋白(Qiagen)和胶原1α1引物(定制序列-有义:5’-TCC-CCA-GCT-GTC-TTA-TGG-CT-3’和反义:5’-CAG-GCA-CGG-AAA-TTC-CTC-C-3’)。持家基因GAPDH用于标准化(定制引物序列:F 5’-ATC-TCT-GCC-CCC-TCT-GCT-G-3’和R 5’-ATG-GTT-CAC-ACC-CAT-GAC-GA-3’;Invitrogen/LifeTechnologies,Carlsbad,CA)。PCR倍数变化(针对GAPDH标准化)由未处理的进行计算。
结果在表3A和3B中示出。
表3A
表3B
1-羟基3,5-双(4’羟基苯乙烯基)苯增加与胶原和弹性蛋白生产相关的基因的表达。
实例4:TNF-α诱导的MMP-9水平的抑制
如下在不同浓度下测试1-羟基3,5-双(4’羟基苯乙烯基)苯抑制TNF-a诱导的MMP-9水平的能力。在不期望的人皮肤中细胞外基质分解中涉及TNF-α诱导的MMP-9的形成。
表皮等同物(EPI 200HCF)购自MatTek(MatTek(Ashland,MA))。在得到时,将所述表皮等同物在37℃下于不含氢化可的松的维持培养基中温育24小时。在用TNF-α(100ng/mL)处理前,将等同物用在70%乙醇/30%丙二醇媒介物中的1-羟基3,5-双(4’羟基苯乙烯基)苯提取物局部处理(2mg/cm2)2小时。使等同物在37℃下与维持培养基一起温育48小时,随后使用商购可得的试剂盒(R&D Systems,Minneapolis,MN)分析上清液的MMP-9。
结果在表4中示出。
表4
1-羟基3,5-双(4’羟基苯乙烯基)苯抑制TNF-α诱导的MMP-9形成。
实例5:黑色素生成抑制测试
来自太阳的紫外线(UV)辐射是最重要的黑色素形成的外部刺激,导致皮肤变黑。减少皮肤中的黑色素形成可通过抑制黑色素生物发生过程的多个步骤来实现。酪氨酸酶是黑色素生成的关键调节酶。抑制酪氨酸酶的试剂将减少黑色素合成。
1-羟基3,5-双(4’羟基苯乙烯基)苯(0.0001、0.001和0.01%w/v)如下就酪氨酸酶抑制进行测试。
蘑菇酪氨酸酶样品(Sigma,T7755,10U/反应)用1-羟基3,5-双(4’羟基苯乙烯基)苯的样品和对照样品进行处理。通过在37℃下添加10mM左旋多巴(Research Organics,#2111D)引发反应。对于对照样品(不暴露于测试化合物)和暴露于测试化合物的测试样品,通过记录在30分钟后在492nm处的光吸收(光密度)来测量酪氨酸酶活性。
酪氨酸酶的抑制百分比通过下式与在492nm处的吸收减少(相对于对照)相关:
酪氨酸酶的抑制百分比=[T对照-T样品/T对照)]*100
其中T对照是对照的酪氨酸酶活性,并且T样品是在测试化合物的存在下的酪氨酸酶活性。样品一式两份进行测试,并且将酪氨酸酶的抑制百分比求平均值并且记录标准差。对照具有0.622的平均光密度。
结果在表5中提供。
表5
1-羟基3,5-双(4’羟基苯乙烯基)苯显示大量和剂量依赖性的酪氨酸酶活性的抑制。
实例6:UV诱导的黑色素生成的抑制
制备一个或多个B16(F10)细胞样品,并且各自用测试样品预处理,随后为如下所述的UVB暴露。处理后,UVB刺激了细胞中黑色素的生成,然后根据测试化合物抑制或降低黑色素生成速率的能力来评价该测试化合物。裂解细胞以在595nm处进行蛋白测量,在470nm处进行黑色素含量测量。通过将测试化合物获得的抑制百分比与处理的对照进行比较,以确定测试化合物的效力。
在第一天时,用约1百万个细胞/板的密度将鼠黑色素瘤B16(F10)细胞接种于60mm板中,并在37℃、5%CO2下温育48小时。第2天,利用预定浓度(例如25μg/mL)的测试化合物处理汇合率为90-100%的细胞两小时(仅限测试化合物样品),然后将其暴露于200mJ/cm2的UVB中(用于测试样品和处理的对照)。在第3天(对测试样品和处理的对照进行UVB照射后24小时)收获细胞,将其在蛋白裂解缓冲液(50mM Tris,pH8,2mM EDTA,150mM NaCl,和1%TRITON×100-购自BioRad的非离子型表面活性剂,目录号:161-0407)中裂解,并且离心。
将所得的上清液与蛋白质染料测定剂(Bio-rad蛋白质测定试剂)充分混合,并且使用分光光度计(Molecular Devices VERSAmax)测定样品在595nm处的光密度(OD),所述光密度(OD)记录为“蛋白质测定OD”。将在上清液去除后剩下的细胞团块溶解于碱性DMSO缓冲液中,并且使用分光光度计类似地测试得到的溶液在470nm处的黑色素吸光度。该吸光度记录为“黑色素测定OD”。
如上所示制备且收获B16(F10)鼠黑色素瘤细胞的对照样品,但不添加任何测试样品,也不暴露于UVB(未处理对照)。如上所示制备且收获其他样品,但不添加测试样品,也不如下所述暴露于UVB(处理对照)。
制备未处理对照、处理对照和每种测试样品各三个样品,并且各自测量黑色素OD和蛋白质OD。通过以下公式计算各未处理对照(3个样品)、处理对照(3个样品)和测试样品(每种测试化合物3个样品)的标准化黑色素:
标准化黑色素=黑色素测定OD/蛋白质测定OD。
计算未处理对照和处理对照的标准化黑色素的平均值(三个计算值的总和/3)。
通过从处理对照的平均标准化黑色素中扣除未处理对照的平均标准化黑色素,测定对照的诱导值(其可视为UV诱导的黑色素增加,没有任何测试样品减少黑色素生成的有益效果)。类似地,随后通过从测试样品的标准化黑色素中扣除未处理对照的平均标准化黑色素,计算每个测试样品的诱导值(其可视为超过且在未用UV处理的样品的基线之上的另外黑色素的量)。随后经由下式计算每个测试样品的抑制百分比:
抑制百分比=100×[(对照的诱导值–测试样品的诱导值)/对照的诱导值]。
平均抑制百分比计算为每个测试样品所得的三个抑制%值的总和除以3。
使用下表6A中的1-羟基3,5-双(4’羟基苯乙烯基)苯-游离酚(0.0001%)的例子,来证实抑制百分比的计算顺序。
表6A:UV诱导的黑色素生成的抑制百分比的实例计算
根据上文描述的UV诱导的黑色素生成测试的抑制来评估1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐。结果在表6B中记录。
表6B:UV诱导的黑色素生成的抑制百分比
1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐显示UV诱导的黑色素生成的强烈抑制。
实例7:色素沉着的抑制
如下使用得自MatTek的MelanoDermTMSystem的皮肤表皮等价组织。MatTek的MelanoDermTMSystem由正常的人源性表皮角质细胞(NHEK)和黑素细胞(NHM)组成,这些细胞已经过培养形成了多层、高度分化的人表皮模型。具体地讲,在以下测试中采用了MEL-300-B组织,每个的直径均为9mm。
1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐在适当媒介物中进行制备,并且每天局部地施用于皮肤模型。该实验持续八天。在第9天进行测量。
使用分光光度计(Konica Minolta CM-2600d)测量每个皮肤模型组织的明度(L值)。使用下式计算每个测试样品的ΔL(与媒介物处理的对照相比较的明度):
ΔL=处理样品的L值-对照样品的L值
结果示于表7中。
表7
明度(ΔL) | |
1-羟基3,5-双(4’羟基苯乙烯基)苯-哌嗪盐(0.1%) | 1.46±0.71 |
1-羟基3,5-双(4’羟基苯乙烯基)苯-哌嗪盐(0.25%) | 2.83±0.41 |
1-羟基3,5-双(4’羟基苯乙烯基)苯-哌嗪盐(0.5%) | 4.60±0.61 |
1-羟基3,5-双(4’羟基苯乙烯基)苯-游离酚(0.5%) | 4.23±0.64 |
1-羟基3,5-双(4’羟基苯乙烯基)苯及其哌嗪盐显示在表皮等价组织中的黑色素生成的抑制。
实例8
1-羟基3,5-双(4’羟基苯乙烯基)苯的活性如下针对代表性革兰氏阳性菌、革兰氏阴性和真菌物种进行评估。
通过在琥珀色小瓶中称重200mg 1-羟基3,5-双(4’羟基苯乙烯基)苯粉末(测试物品)且在室温下通过涡旋将其溶解于5mL DMSO中,来制备4%(40mg/mL)原液。
基于标准美国临床实验室标准化委员会(National Committee for ClinicalLaboratory Standards)(NCCLS)方案(NCCLS,2000),通过肉汤测定进行抗微生物敏感性测试,以测定测试物品的最小抑制浓度(MIC)。该测定中的MIC定义为抑制处于研究下的微生物的可见生长的测试物品的最低浓度。
测试七种不同的微生物:三(3)种革兰氏阳性菌(金黄色葡萄球菌(MO-012-015)、表皮葡萄球菌(MO-012-045)和痤疮丙酸杆菌(ATCC#6919)),两(2)种革兰氏阴性菌(大肠杆菌(ATCC#8739)和铜绿假单胞菌(ATCC#9027)),以及两(2)种真菌物种(白假丝酵母(ATCC#10231)和黑曲霉(ATCC#16404))。除葡萄球菌属物种外的所有物种均得自美国典型培养物中心(ATCC)。两(2)个葡萄球菌属物种作为临床分离物获得。
使用由测试物品的原始4%w/v母液制备的稀释物,以获得1.00%w/v起始浓度和0.25%w/v起始浓度的制剂用于测定,对于测试物品测定七种菌株各自的MIC。
抗微生物敏感性测试在96孔微量滴定板中进行。在该测定中,测试物品起始浓度的两倍稀释沿微量滴定板的前10行序贯进行(第11和12行充当测试生物体的阳性对照和阴性对照)。
对于每种测试生物体制备接种物的悬浮液,并且调整至在600nm下的光密度(OD600)的浊度。将该接种物1:100稀释,并且将100ul加入微量滴定板的每个孔中,以获得约1×106CFU/孔的最终接种物。
将板覆盖并且对于细菌在35℃下温育(痤疮丙酸杆菌在厌氧条件下温育),并且对于真菌在25℃下温育。微板在48小时后进行检查,并且就MIC进行测定(痤疮丙酸杆菌温育约72小时,并且真菌属物种板温育约120小时)。MIC是在温育后通过目视读数未获得生长的抗微生物剂的最低浓度。
最小杀生物浓度(MBC)测定设计为测定在其下测试物品将证实针对特定微生物的杀细菌或杀真菌特性的最低浓度。在分析MIC板后,使96实心针多印迹复制器(Solid PinMulti-Blot Replicator)火焰消毒,冷却且对齐,使得每根针浸泡到MIC微量滴定板的一个孔内。复制器随后用于印迹新鲜的琼脂板,使得来自MIC微量滴定板孔的小体积等分试样浸渍在MBC板的琼脂基质中。微板在48小时后进行检查,并且就MBC进行测定(痤疮丙酸杆菌温育约72小时,并且真菌属物种板温育约120小时)。最小杀生物浓度(MBC)定义为其中不存在细菌或真菌生长的杀生物剂的最小浓度。
针对每种测试生物体计算测试物品的MIC和MBC值。结果在表8中示出。
表8
数据呈现为以(%,w/v)的值表示的MIC或MBC(最小抑制浓度或最小杀生物浓度),并且证实发现1-羟基3,5-双(4’羟基苯乙烯基)苯抑制革兰氏阳性菌、革兰氏阴性菌和真菌物种的生长。该化合物还证实针对革兰氏阳性菌和酵母物种的杀生物活性。这些数据还提出与革兰氏阴性菌和霉菌相比较,1-羟基3,5-双(4’羟基苯乙烯基)苯具有增强的针对革兰氏阳性菌和酵母的活性。
实例9
通过将表9中的成分共混来制备根据本发明的组合物。
表9
将水加入处理容器中。开始混合,加入盐并混合直到溶解。施加热并混合继续直至达到85℃。将1-羟基3,5-双(4’羟基苯乙烯基)苯溶解于甘油中,随后在继续混合的同时加入,并且将温度维持在85℃下。加入二硬脂基二甲基氯化铵,连同凡士林和十二烷基十六醇、聚二甲基硅氧烷和棕榈酸异丙酯。使组合物在85℃下混合另外10-15分钟。随后使该组合物去除热,混合且冷却。在40℃下,加入苄醇,加入适量水,混合且冷却至30-35℃。随后将该组合物填充到包装内。
通过将表10中的成分共混来制备根据本发明的组合物。
表10
将水加入处理容器中,并且将温度设为85℃。开始混合,加入甘油且混合直至溶解。加入VARISOFT TA-100,连同凡士林和ISOFOL 28、道康宁Q7-912020CS和棕榈酸异丙酯。使组合物在85℃下混合另外10-15分钟。随后使该组合物去除热,混合且冷却。
通过将表11中的成分共混来制备根据本发明的组合物。
表11
将1-羟基3,5-双(4’羟基苯乙烯基)苯称重并且溶解于HYDROLITE 5中,并且加入去离子水以形成相A。使油质体和FINSOLV TN混合以形成相B。在连续混合下将相B非常缓慢地加入相A。继续混合15分钟直至形成均匀的乳液。在以高速度的持续混合下将ARISTOFLEX加入该乳液中,以获得浓稠、平滑且均质的制剂。
通过将表12中的成分共混来制备根据本发明的组合物。
表12
通过将FINSOLV TN加入清洁的玻璃烧杯来制备油相。开始搅动并且使容器加热至55-60℃。当油相达到55℃或更高温度时,加入Brij 72和Brij 721。当油相达到55-60℃时,使它保持在该温度并混合15分钟(或直至均匀)。随后将温度保持在55-60℃下,伴随混合直至加入水相中。
通过将水加入到干净的玻璃烧杯中制备水相。开始搅动并且使容器加热至55-60℃。加入乙二胺四乙酸二钠。在55-60℃下,将成分混合15分钟或直到均匀。随后将温度保持在55-60℃下,伴随混合以定相。
伴随增加的搅拌将油相加入到水相中,并且随后以高速混合10-20分钟。在50℃或更低的温度下,加入聚二甲基硅氧烷。在40℃或更低的温度下,加入PHENONIP XB。然后将两相混合10分钟或直到均匀。加入氢氧化钠(目标pH为5.4)。随后将组合物混合10分钟或直到均匀。随后加入LYS’LASTINE和SYMMATRIX。将1-羟基3,5-双(4’羟基苯乙烯基)苯称重并且溶解于甘油中,并且加入混合物中,将所述混合物混合直至均匀。随后将水加到适量,并且将组合物混合另外10分钟。
应当了解,虽然已结合本发明的具体实施方式描述了本发明,但是前述描述旨在说明而非限制由随附权利要求书所限定的本发明的范围。其他方面、优点和修改均在权利要求书范围内。
Claims (23)
1.一种组合物,所述组合物包含:
1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐;
防晒剂;和
美容上可接受的局部用载体,所述美容上可接受的局部用载体包含选自润湿剂、乳化剂、润肤剂、湿润剂和芳香剂的成分。
2.根据权利要求1所述的组合物,其中所述美容上可接受的局部用载体包含选自下述种类中的至少两种的成分:润湿剂、乳化剂、润肤剂、湿润剂和芳香剂。
3.根据权利要求1所述的组合物,其中所述美容上可接受的局部用载体包含润肤剂和乳化剂。
4.根据权利要求1所述的组合物,其中所述美容上可接受的局部用载体包含选自下述种类中的至少三种的成分:润湿剂、乳化剂、润肤剂、湿润剂和芳香剂。
5.根据权利要求1所述的组合物,所述组合物还包含另外的NFKB抑制剂。
6.根据权利要求1所述的组合物,其中所述组合物包含0.01%至10%的所述1-羟基3,5-双(4’羟基苯乙烯基)苯或其盐。
7.根据权利要求1所述的组合物,所述组合物还包含亮肤剂。
8.根据权利要求1所述的组合物,所述组合物不含防腐剂。
9.根据权利要求8所述的组合物,其中所述防腐剂选自对羟基苯甲酸酯类、苯甲酸及其盐、苯氧基乙醇、异噻唑酮、咪唑烷基脲、碘代丙炔基氨基甲酸丁酯、DMDM乙内酰脲、辛乙二醇、脱氢乙酸、山梨酸及其盐、氯苯甘醚、辛酸甘油酯、苯丙醇、乙酰丙酸钠、茴香酸、乙基己基甘油、苯甲醇、以及它们的组合。
10.一种用于非治疗目的的处理人皮肤的方法,所述方法包括向所述人皮肤局部地施用如权利要求1所述的组合物。
11.一种非治疗目的的处理皮肤老化迹象的方法,所述方法包括向需要此类处理的皮肤局部地施用如权利要求1所述的组合物。
12.根据权利要求11所述的方法,其中所述皮肤老化迹象选自细纹和皱纹、弹性丧失、肤色不均和斑点。
13.一种用于非治疗目的的亮肤方法,所述方法包括向需要亮肤处理的皮肤局部地施用如权利要求1所述的组合物的步骤。
14.根据权利要求10所述的方法,其中使用选自面膜和擦拭物的施用器来施用所述组合物。
15.一种非治疗目的抑制微生物生长的方法,所述方法包括向所述微生物施用如权利要求1所述的组合物。
16.根据权利要求15所述的方法,其中,所述组合物包含按重量计0.02%至1%的1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐。
17.根据权利要求1所述的组合物在制备用于处理人皮肤的药物中的应用,包括向所述人皮肤局部地施用所述组合物。
18.根据权利要求1所述的组合物在制备用于处理皮肤老化迹象的药物中的应用,包括向需要此类处理的皮肤局部地施用所述组合物。
19.根据权利要求18所述的应用,其中所述皮肤老化迹象选自细纹和皱纹、弹性丧失、肤色不均和斑点。
20.根据权利要求1所述的组合物在制备用于亮肤的药物中的应用,所述应用包括向需要亮肤处理的皮肤局部地施用所述组合物。
21.根据权利要求20所述的应用,其中使用选自面膜和擦拭物的施用器来施用所述组合物。
22.根据权利要求1所述的组合物在制备用于抑制微生物生长的药物中的应用,所述应用包括向所述微生物施用所述组合物。
23.根据权利要求22所述的应用,其中,所述组合物包含按重量计0.02%至1%的1-羟基3,5-双(4’羟基苯乙烯基)苯或其美容上可接受的盐。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/537,959 | 2012-06-29 | ||
US13/538,017 | 2012-06-29 | ||
US13/537,959 US8846013B2 (en) | 2012-06-29 | 2012-06-29 | Topical application of 1-hydroxyl-3,5-BIS(4′hydroxy styryl)benzene |
US13/538,017 US20140005275A1 (en) | 2012-06-29 | 2012-06-29 | Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene |
US13/538,054 US8758731B2 (en) | 2012-06-29 | 2012-06-29 | Skin lightening by topical application of 1-hydroxyl 3,5-bis(4′hydroxyl styryl)benzene |
US13/538,054 | 2012-06-29 | ||
PCT/US2013/046354 WO2014004177A2 (en) | 2012-06-29 | 2013-06-18 | Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104411288A CN104411288A (zh) | 2015-03-11 |
CN104411288B true CN104411288B (zh) | 2017-10-17 |
Family
ID=48741561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380035518.2A Expired - Fee Related CN104411288B (zh) | 2012-06-29 | 2013-06-18 | 1‑羟基3,5‑双(4’羟基苯乙烯基)苯的局部施用 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2866779A2 (zh) |
KR (1) | KR20150023891A (zh) |
CN (1) | CN104411288B (zh) |
AU (1) | AU2013280916B2 (zh) |
BR (1) | BR112014032739A2 (zh) |
CA (1) | CA2877471A1 (zh) |
RU (1) | RU2648763C2 (zh) |
WO (1) | WO2014004177A2 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840399B (zh) * | 2015-05-18 | 2018-10-23 | 中山安理汇日用品有限公司 | 具备自防腐特性的紧肤霜配方 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031122A1 (de) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Neue curcumin/tetrahydrocurcumin-derivate für den einsatz in kosmetika, pharmazeutika und bei der ernährung |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113388A1 (en) * | 2001-12-13 | 2003-06-19 | Dung Phan | Methods of treatment for skin disorders using turmeric extract and a hydroxy acid |
RU2383341C2 (ru) * | 2007-11-29 | 2010-03-10 | Ольга Викторовна Кухарева | Способ омоложения кожи |
US7745670B2 (en) | 2008-06-27 | 2010-06-29 | Codman & Shurtleff, Inc. | Curcumin-Resveratrol hybrid molecule |
KR101095026B1 (ko) * | 2009-01-23 | 2011-12-20 | 한국과학기술연구원 | 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물 |
BR112012007512A2 (pt) * | 2009-10-02 | 2016-11-22 | Johnson & Johnson Consumer | composições compreendendo uma mistura anti-inflamatória |
-
2013
- 2013-06-18 RU RU2015102833A patent/RU2648763C2/ru not_active IP Right Cessation
- 2013-06-18 CN CN201380035518.2A patent/CN104411288B/zh not_active Expired - Fee Related
- 2013-06-18 AU AU2013280916A patent/AU2013280916B2/en not_active Ceased
- 2013-06-18 WO PCT/US2013/046354 patent/WO2014004177A2/en active Application Filing
- 2013-06-18 CA CA2877471A patent/CA2877471A1/en not_active Abandoned
- 2013-06-18 EP EP13733189.8A patent/EP2866779A2/en not_active Withdrawn
- 2013-06-18 KR KR20157002114A patent/KR20150023891A/ko not_active Application Discontinuation
- 2013-06-18 BR BR112014032739A patent/BR112014032739A2/pt not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031122A1 (de) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Neue curcumin/tetrahydrocurcumin-derivate für den einsatz in kosmetika, pharmazeutika und bei der ernährung |
Also Published As
Publication number | Publication date |
---|---|
BR112014032739A2 (pt) | 2017-06-27 |
AU2013280916A1 (en) | 2015-01-22 |
RU2015102833A (ru) | 2016-08-20 |
EP2866779A2 (en) | 2015-05-06 |
WO2014004177A3 (en) | 2014-08-07 |
CN104411288A (zh) | 2015-03-11 |
KR20150023891A (ko) | 2015-03-05 |
WO2014004177A2 (en) | 2014-01-03 |
CA2877471A1 (en) | 2014-01-03 |
RU2648763C2 (ru) | 2018-03-28 |
AU2013280916B2 (en) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103989589B (zh) | 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物 | |
CN101917965A (zh) | 局部化妆用皮肤增亮组合物及其使用方法 | |
RU2572505C2 (ru) | КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОР NFкВ И СТИМУЛЯТОР ОБРАЗОВАНИЯ ТРОПОЭЛАСТИНА | |
Yang et al. | Dietary enzyme-treated Hibiscus syriacus L. protects skin against chronic UVB-induced photoaging via enhancement of skin hydration and collagen synthesis | |
CA3011834C (en) | Skin cosmetic composition comprising saccharin, maltol, and theobromine | |
US20160095815A1 (en) | Substance for restoring normal co-expression and interaction between the lox and nrage proteins | |
CN103402494B (zh) | 使用包含榕树、莲花和三叶草浆液组分的组合物改善老化皮肤外观的方法 | |
CN110325246A (zh) | 防晒组合物 | |
KR101735350B1 (ko) | 필란투스 니루리의 추출물 | |
CN104411288B (zh) | 1‑羟基3,5‑双(4’羟基苯乙烯基)苯的局部施用 | |
CN104244923A (zh) | 用于改善面部毛孔外观的组合物和方法 | |
CN103491943B (zh) | 包含榕树、莲属植物和三叶草浆液级分的组合物(老化) | |
US8846013B2 (en) | Topical application of 1-hydroxyl-3,5-BIS(4′hydroxy styryl)benzene | |
KR100406124B1 (ko) | 자외선에 의해 증가하는 프로스타글란딘을 억제하는성분과 멜라닌 합성을 억제하는 성분을 동시에 함유하는미백 화장료 조성물 | |
EP2218441A1 (en) | Methods for the prevention and/or treatment of age spots | |
CN104822364A (zh) | 包含取代的苯酚的组合物及其局部施用 | |
KR20210129462A (ko) | 흰무늬엉겅퀴씨 추출물을 유효성분으로 포함하는 하이드로겔 제형의 화장료 조성물 | |
JP2004075573A (ja) | 皮膚化粧料 | |
Fonseca et al. | Antiaging effects of a skin care formulation containing nanoencapsulated antioxidants: A clinical, in vitro, and ex vivo study | |
US8758731B2 (en) | Skin lightening by topical application of 1-hydroxyl 3,5-bis(4′hydroxyl styryl)benzene | |
US20240091294A1 (en) | Extract of Top Growth of Holy Basil, and Cosmetic or Dermatological Compositions Containing Same | |
US20150257992A1 (en) | Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene | |
US20140005275A1 (en) | Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171017 Termination date: 20200618 |
|
CF01 | Termination of patent right due to non-payment of annual fee |